MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585084 | Name: RFCNU

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RFCNU is a nitrosourea derivative.

Chemical Structure

RFCNU
RFCNU
CAS#56194-22-0

Theoretical Analysis

MedKoo Cat#: 585084

Name: RFCNU

CAS#: 56194-22-0

Chemical Formula: C18H21ClN4O9

Exact Mass: 472.0997

Molecular Weight: 472.84

Elemental Analysis: C, 45.72; H, 4.48; Cl, 7.50; N, 11.85; O, 30.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
RFCNU
IUPAC/Chemical Name
Urea, N-(2-chloroethyl)-N'-(2,3-O-(1-methylethylidene)-5-O-(4-nitrobenzoyl)ribofuranosyl)-N-nitroso-
InChi Key
YASNUXZKZNVXIS-CBNXCZCTSA-N
InChi Code
InChI=1S/C18H21ClN4O9/c1-18(2)31-13-12(9-29-16(24)10-3-5-11(6-4-10)23(27)28)30-15(14(13)32-18)20-17(25)22(21-26)8-7-19/h3-6,12-15H,7-9H2,1-2H3,(H,20,25)/t12-,13-,14-,15?/m1/s1
SMILES Code
O=C(NC1[C@@H]([C@@H]([C@@H](COC(C2=CC=C([N+]([O-])=O)C=C2)=O)O1)O3)OC3(C)C)N(CCCl)N=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 472.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bourut C, Chenu E, Godenèche D, Madelmont JC, Maral R, Mathé G, Meyniel G. Cytostatic action of two nitrosoureas derived from cysteamine. Br J Pharmacol. 1986 Nov;89(3):539-46. PubMed PMID: 3801787; PubMed Central PMCID: PMC1917164. 2: Andrade Mena CE, Orbach-Arbouys S, Cosmatopoulos K, Mathé G. Effects of three new nitrosourea analogs (CNCC, RFCNU and chlorozotocin) on in vivo destruction of L 1210 leukemia cells and on the immune response. Chemotherapy. 1986;32(2):131-7. PubMed PMID: 2938892. 3: Maral R, Bourut C, Chenu E, Mathe G, Bernon R, Lussan C, Imbach JL, Schein P, Bothorel P. Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state. Oncology. 1985;42(2):122-8. PubMed PMID: 3157909. 4: Blazsek I, Mathé G, Maral R, Jasmin C. In vivo acute hematotoxicity of N,N'-bis[N-(2-chloroethyl)-N-nitrosocarbamoyl]cystamine (CNCC), a new nitrosourea analog. Toxicol Appl Pharmacol. 1984 Jun 30;74(2):250-7. PubMed PMID: 6740675. 5: Rebischung JL, Gougeon MD, Mori KJ, Lemaigre G, Mathé G, Jasmin C. Hematological toxicity of repeated injections of (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea. Cancer Res. 1984 Feb;44(2):503-6. PubMed PMID: 6692356. 6: Florentin I, Hayat M, Kiger N, Mathé G, Maral J, Imbach JL. Comparative analysis of the immunopharmacological properties of three new nitrosourea analogues: RPCNU, RFCNU and Chlorozotocin. Int J Immunopharmacol. 1983;5(3):201-10. PubMed PMID: 6225736. 7: Madelmont JC, Moreau MF, Godeneche D, Duprat J, Plagne R, Meyniel G. Main metabolites of 1-(2-chloroethyl)-3-[1'-(5'-p-nitrobenzoyl-2',3'-isopropylidene)-alpha, beta-D-ribofuranosyl]-1-nitrosourea and 1-(2-chloroethyl)-3-(2',3', 4'-tri-O-acetyl-alpha, beta-D-ribopyranosyl)-1-nitrosourea in rats. Drug Metab Dispos. 1982 Nov-Dec;10(6):662-6. PubMed PMID: 6130919. 8: Mathé G, Schein PS, De Vassal F, Serrou B, Imbach JL. [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)]. Sem Hop. 1982 Sep 16;58(33):1867-71. French. PubMed PMID: 6293062. 9: Mathe G, Schein P, MacDonald JS, Imbach JL, Misset JL, De Vassal F, Ribaud P, Serrou B, Gouveia J, Musset M, Machover D, Schwarzenberg L, Jasmin C, de Jager R. Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNU. Eur J Cancer Clin Oncol. 1982 Aug;18(8):727-32. PubMed PMID: 6891323. 10: Mathé G, Bothorel P. In vivo enhancement of the experimental oncostatic effect of RFCNU by its encapsulation in liposomes. Biomedicine. 1981 Dec;35(7-8):201-2. PubMed PMID: 7346064. 11: Levallois C, Mani JC, Montero JL, Oiry J, Imbach JL. Action of three nitrosoureas on human lymphocytes. Hypothesis of a specific effect on lymphocyte subpopulations. Farmaco Sci. 1981 Nov;36(11):947-56. PubMed PMID: 7308461. 12: Vlaeminck MN, Collyn-d'Hooghe M, Cappelaere P, Biserte G, Oiry J, Montero JL, Imbach JL. Flow cytofluorometric analysis of the effects of new nitrosourea derivatives on proliferation of EMT 6 tumor cells "in vitro". Biomedicine. 1981 Mar;35(1):27-9. PubMed PMID: 7016209. 13: Mori KJ, Jasmin C, Hayat M, MacDonald JS, Mathé G. In vivo study of acute hematotoxicity of three nitrosoureas, chlorozotocin (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea, and (chloro-2-ethyl)-1-ribopyranosyl-3-nitrosourea. Cancer Res. 1980 Nov;40(11):4282-6. PubMed PMID: 6451285. 14: Godenèche D, Madelmont JC, Moreau MF, Montoloy D, Plagne R. Disposition of the carcinostatic agent 1-(2-chloroethyl)-3-[1'-(5'-p-nitrobenzoyl-2',3'-isopropylidene)-alpha,beta-d-rib ofuranosyl]-1-nitrosourea in animals. Cancer Res. 1980 Sep;40(9):3351-6. PubMed PMID: 7427947. 15: Lemoine R, Gouyette A. Stability and preliminary pharmacokinetic studies of 1-(2-chloroethyl)-3-[1-(5'-paranitrobenzoyl-2',3'-isopropylidene)-alpha, beta-D-ribofuranosyl]-1-nitrosourea (RFCNU), a nonimmunosuppressive nitrosourea. Cancer Treat Rep. 1979 Aug;63(8):1335-41. PubMed PMID: 38907. 16: Meyniel G, Godenech D. [Relationship of labeled molecules in the pharmacokinetic study of alkylating agents (chlorambucil, melphalan, mitoclomine) and glycosyl nitrosoureas (RFCNU and RPCNU)]. Nouv Rev Fr Hematol. 1979;Suppl:XXXIII-XXXV. French. PubMed PMID: 545309. 17: Hayat M, Bourut C, Chenu E, Montero JL, Imbach JL, MacDonald JS, Mathé G. Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice. Cancer Chemother Pharmacol. 1979;3(4):217-21. PubMed PMID: 161207. 18: Mathé G, Serrou B, Hayat M, De Vassal F, Misset JL, Schwarzenberg L, Machover D, Ribaud P, Belpomme D, Jasmin C, Musset M, Montero JL, Imbach JL. Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours. Biomedicine. 1977 Nov;27(8):294-7. French. PubMed PMID: 339971. 19: Imbach JL, Montero JL, Moruzzi A, Serrou B, Chenu E, Hayat M, Mathe G. The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals. Biomedicine. 1975 Dec 20;23(10):410-3. PubMed PMID: 1222217.

View History

Desmethyl-HD-800

Desmethyl-HD-800

Monodesmethyl sumatriptan

Monodesmethyl sumatriptan

Norethindrone isonicotinyl hydrazone

Norethindrone isonicotinyl hydrazone